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Abstract 
Introduction 
Schizophrenia is a chronic and debilitating mental illness characterised by periods of relapse which 
require resource intensive management. Quantifying the cost of relapse is central to the evaluation 
of the cost-effectiveness of treating schizophrenia.  
Objectives 
We aimed to undertake a comprehensive search of the available literature on the cost of relapse 
Methods 
We performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health 
Management Information Consortium) for any study reporting a cost of relapse or data from which 
such a cost could be calculated. Costs are reported in 2015 international dollars. 
Results 
We found 16 studies reporting costs associated with relapse over a defined period of time and 
identified a cost associated with hospitalisation for relapse in 43 studies. Eight clinical decision 
analyses also provided cost estimates. Studies from the US report excess costs of relapse in the 
range $6,033 to $32,753 (2015 PPP$) over periods of 12-15 months.  European studies report excess 
costs in the range $8,665 to $18,676 (2015 PPP$) over periods of 6-12 months. Estimates of the cost 
of hospitalisation for relapse are more diverse, and associated with marked differences in typical 
length of stay across jurisdictions. 
Conclusions 
Wide ranges in the estimated cost of relapse may reflect differences in sample section and relapse 
definition as well as practice styles and differences in resource costs. Selection of the most 
appropriate cost estimate should be guided by the definition of relapse and the analysis setting. 
Key Points 
 Estimates of the excess cost of relapse in schizophrenia range from $9,000 to $19,000 (2015 
USD) in European settings 
 Estimates of the excess cost of relapse in schizophrenia range from $16,000 to $33,000 in US 
settings over periods of 6-15 months 
 Estimates of the cost of hospitalisation for relapse are more diverse due to large differences 
in clinical practice regarding length of stay as well as differences in unit costs across settings 
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1. Introduction 
Schizophrenia is a lifelong, chronic and severely debilitating mental illness that often strikes in young 
adulthood [1]. Mangalore and Knapp estimated the cost of schizophrenia in England at £6.7billion 
per year, £2billion of which was direct costs falling primarily on health and social care budgets [2]. 
Similar estimates for the US indicate an overall cost of $156billion (2013 USD) of which $38billion 
was consumed in direct health care costs [3]. The annual societal cost per patient may be as high as 
$95,000 (2015 USD), and the lifetime costs approaching $1million [4]. Whilst such cost of illness 
estimates are valuable in highlighting the seriousness of mental illness, they do not provide a direct 
estimate of the impact on costs of alternative intervention strategies to treat schizophrenia. The 
main goal of treatment for schizophrenia is to prevent relapse into a psychotic state. Relapse 
frequently necessitates hospitalisation and is potentially resource intensive. Quantifying the cost of 
relapse is essential to understanding the cost-effectiveness of treating schizophrenia. 
Quantifying the cost of relapse requires a clear definition of what constitutes a relapse. The most 
commonly used measure of relapse is hospitalisation due to exacerbation of symptoms [5,6]. 
Relapse is also identified through clinical assessment of exacerbation of symptoms, including the use 
of outcome measures such as the Positive and Negative Syndrome Scale (PANSS) [7]. Violence, 
arrest, self-harm, suicide and suicidal ideation are also sometimes taken to indicate relapse. 
Ambiguity as to what constitutes a relapse probably explains the relative small number of 
publications purporting to report a cost of relapse despite the funding of a number of large, 
observational studies specifically designed to evaluate the cost of supporting schizophrenia patients 
over the last 20 years [8-10]. 
Three principal approaches to costing a relapse can be distinguished in the literature dependent 
upon how relapse is defined. The first approach accommodates any definition of relapse and relies 
on obtaining costs over a fixed period of time. This approach is well suited to both prospective, 
observational studies and analyses of administrative datasets, although the latter usually limits the 
method of identification of relapse. Such an approach also facilitates the estimation of the excess 
cost of relapse over and above the cost of patients in remission. The second approach equates 
relapse with hospitalisation for relapse and costs the hospital stay. This approach is not well suited 
to estimating the excess costs of relapse but avoids the need to define an arbitrary time period over 
which to collect costs with the risk that such a period is insufficiently long, or includes multiple 
relapse episodes. The third approach utilises expert clinical opinion on likely resource use, 
sometimes in combination with data from administrative databases on length of hospital stay. 
The aim of this study is to review the literature on the cost of relapse in schizophrenia. Within the 
framework outlined above we sought to identify all de novo estimates of the cost of relapse. We 
included papers where such a cost is not explicitly reported but could be determined from reported 
data. We have calculated excess costs of relapse where reported data allowed but the authors had 
not explicitly done so. We also provide a cost inflated to 2015 USD after conversion at purchasing 
power parity rates to facilitate comparison of studies. 
2. Methods 
A structured search of MEDLINE, Embase, PsycINFO and Health Management Information 
Consortium (HMIC) was undertaken to identify articles published before January 2017 (November 
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2016 for HMIC) using the following search strategy ‘Cost$’[Title/abstract/keyword] AND 
‘schizophrenia’[Title/abstract/keyword] AND {‘Relapse’[Title/abstract/keyword] OR ‘Hospitali$’ 
[Title/abstract/keyword]}. The search strategy is reported in detail in the supplementary material. 
The retrieved records were checked for duplicates, but no further limitations were applied prior to 
screening. The UK databases NHSEED, DARE and HTA were also searched using modified versions of 
the above search terms. References and citations of all identified relevant articles were also 
searched. We applied the following inclusion criteria: 
1. Publications in English 
2. The relevant population were wholly or predominantly diagnosed with schizophrenia or 
schizoaffective disorder 
3. The study provided an estimate of the cost of relapse and not simply an indication of 
resource use such as length of stay in hospital 
4. Conference abstracts with an estimate of the cost of relapse discernible from a published 
record 
5. Top-down costing studies with data on the incidence of relapse or the prevalence of 
schizophrenia which allowed a calculation of the cost of relapse 
6. Estimates based on expert opinion 
Studies were excluded if they reported length of stay (LOS) but provided no data on associated costs. 
We excluded decision analyses which assumed a cost of hospitalisation as a fixed reimbursement 
tariff for a psychiatric inpatient stay regardless of LOS. Modelling studies were excluded if relapse 
costs were inflated estimates from a published source. We included papers where a cost of relapse 
or hospitalisation for relapse could be calculated from the data presented for the entire cohort of 
patients relapsing; we excluded papers in which this calculation was only possible for a subgroup of 
relapsing patients. Data were abstracted and reviewed by the first author (MP). Studies were 
classified into the following categories: those reporting costs over a defined time period; those 
reporting a cost per hospitalisation for relapse; and those drawing on expert opinion to estimate 
costs. The latter studies were exclusively clinical decision analyses. Studies reporting costs over a 
defined period were subdivided into those reporting all-cause medical costs, mental health costs and 
schizophrenia related costs; where all-cause and schizophrenia related costs were reported we 
tabulate both. Given the varied nature of the studies we did not apply a formal quality appraisal 
procedure. 
Frequently, data were reported which allowed calculation of a cost of hospitalisation but the cost 
was not reported. Mean LOS and mean cost of hospitalisation was calculated by dividing total LOS 
and total hospital costs by the mean number of inpatients stays where such data were reported. 
Where data were reported for both baseline and follow-up periods we combined data prior to 
calculation of mean LOS and mean hospital cost. Where data were reported by subgroup to facilitate 
comparison of treatment regimes we combined the data across subgroups prior to calculating mean 
LOS and mean hospital costs (effectively, we calculated a weighted mean across subgroups). Where 
costs were reported for patients who relapsed and patients who did not we calculate the excess cost 
of relapse as the difference between the two costs. Where costs are reported in USD after 
conversion we report costs in both USD and home currency. Costs in home currency were converted 
to Purchasing Power Parity dollars using OECD values [11] and inflated to 2015 prices using a 
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published conversion tool [12]. A price year was estimated for publications which failed to clarify the 
relevant year.  
We undertook regression analysis to explore the influence of potential cost drivers on the cost of 
relapse and the cost of hospitalisation for relapse. We used generalised linear modelling and did not 
account for the relative size of different studies. The cost drivers we examined were price year (as a 
measure of how long ago the study was undertaken), per capita gross domestic product (GDP) for 
the country of origin and whether or not the study originated in the US. The latter two variables 
have been shown to be strong predictors of hospital costs [13]. For the cost of hospitalisation of 
relapse we also included mean LOS. For the cost of relapse we also included the duration of the 
relapse period. Price year was specified as the number of years after 1992. All costs and GDP values 
were expressed in 2015 PPP$. Schizophrenia-related costs were prioritised over mental health 
related costs over all-cause costs where a study reported costs in multiple categories. In the analysis 
of the cost of relapse, dummy variables were used to control for differences arising from the 
reporting of mental health related or all cause costs rather than schizophrenia costs. Given the 
expected skew in the dependent variables we assumed a gamma distribution. We also assumed a 
multiplicative effect of the independent variables as is commonly observed for cost data. Given the 
inevitably small sample size, tests of distributional form and link function would have been 
underpowered and possibly misleading so we did not use them to guide model selection. Covariate 
selection was guided by Akaike’s Information Criteria [14]. 
3. Results 
Our searches returned 1,931 abstracts, of which 196 were identified as potentially relevant (Figure 
1). From these, 174 papers were retrieved and reviewed. Six conference abstracts and 57 papers 
were identified as providing relevant data. 
3.1 Studies reporting costs associated with relapse over a defined period 
Sixteen papers reported costs of relapse over a defined period of observation (table 1). The studies 
originated from US (5) [10,15-18], UK (1) [19], Germany (2) [20,21], Brazil (1) [22], Singapore (1) [23], 
China (2) [24,25], Australia (1) [26], and Sweden (1) [27], with the remaining two pan-European 
[28,29]. All were based on retrospective analysis of clinical or administrative data and used a 
bottom-up costing approach. Thirteen studies allowed calculation of an excess cost of relapse from 
comparison of data on relapsing and non-relapsing patients [10,15-20,23-28] and one paper 
reported the proportional cost increase associated with relapse without reporting the raw costs [21]. 
The majority of studies reported costs over one year [10,16,17,20,22-26,28]; one study reported 
costs over 15 months [18]; three studies reported costs over 6 months [19,21,27]; one study 
reported costs over three months [29] and one study reported costs over one week [15]. The 
majority of studies reported mental health related costs [10,18,19,21-23,25-27,29]. Six studies 
reported all cause health costs [15-17,20,24,25], of which three also reported schizophrenia related 
costs [15,16,20], one study also reported total costs [24], and one study reported all-cause, mental 
health related and schizophrenia related costs [25]. One study reported solely schizophrenia related 
costs [28]. Most studies included adults with a diagnosis of schizophrenia [10,15-23,26-29]. US 
studies exploiting administrative data generally identified patients using International Classification 
of Disease (ICD)-9 codes without excluding schizophreniform and schizoaffective disorder [15-17]; 
German studies used ICD-10 codes which excluded schizophreniform and schizoaffective disorder 
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[20,21]. The majority of studies exploiting administrative data defined relapse as a psychiatric 
hospitalisation, although one study included emergency room visits [16], and one study defined 
relapse as periods of relative or absolute increase in costs [15]. Studies collecting data prospectively 
typically applied wider criteria to define relapse which included deterioration in psychiatric health 
status and suicide attempts [10,28]. 
Costs included were not always clearly stated but all studies appeared to include inpatient, 
outpatient and drug costs. Three European studies included wider costs: sickness payments (sick 
leave) [20], vocational costs [19,21] and accommodation costs [21]. One study from China included 
direct non-medical costs and indirect costs relating to crime and productivity [24].  Unsurprisingly, 
costs were generally higher in US studies and where costs were reported over a longer period. 
Where studies reported all-cause and schizophrenia related costs, schizophrenia related costs were 
30-92% of the all-cause costs. The difference was larger for the overall cost of relapse than for the 
excess cost, and for the US studies compared to the Chinese and German study. The latter may 
reflect differences in the quality of diagnostic data. However, studies reporting all-cause costs did 
not provide the largest cost estimates; larger estimates were derived from studies reporting mental 
health related costs. This pattern might suggest that whilst hospitalisation episodes were not always 
correctly identified as a schizophrenia related episode they were generally identified as a mental 
health related episode, and further, that the majority of hospitalisations in this population are 
related to mental health.  
The overall cost of relapse for US studies reporting over 12-15 months ranged from $16,848 to 
$48,442 (2015 PPP$); the excess cost of relapse for the same studies ranged from $6,033 to $32,753. 
The study which provided the lowest cost estimate for both overall and excess costs included 
emergency room visits in the definition of relapse [16], which is likely to have expanded the scope of 
the study to include lower cost episodes. Amongst the studies from Europe and Australia the overall 
cost of relapse ranged from $10,515 to $26,865 (2015 PP$) and the excess cost of relapse ranged 
from $8,665 to $18,676 (2015 PPP$). Costs were generally higher for the studies reporting costs over 
one year. Costs were lower in studies undertaken outside Europe, US and Australia; overall relapse 
costs ranged from $2,760 to $9,290 and excess relapse costs ranged from $4,263 to $6,524 (2015 
PPP$). Across all studies, the relative cost increase associated with relapse ranged from 103% to 
1137% of costs for patients who had not relapsed. 
Regression analysis indicated the natural logarithm of GDP was a modest predictor of the overall 
cost of relapse (p = 0.037) but not the excess cost of relapse. US country of origin was not a 
significant predictor of overall or excess costs. After eliminating the dummy for US studies, costs 
rose with the length of the period defining relapse, increasing by around 15% per month for both 
overall and excess costs (overall costs, p = 0.001; excess costs, p = 0.002). Perhaps surprisingly, costs 
fell for newer studies, decreasing by around 7% for each year beyond 1992 for overall costs and by 
around 12% for each year beyond 1992 for excess costs (overall costs, p = 0.011; excess costs, p = 
0.001). 
 3.2 Studies reporting a cost of Hospitalisation for relapse 
Forty-three studies either reported a cost per hospitalisation for relapse or provided sufficient data 
to calculate a mean cost (table 2) [16,25,27,28,30-69]. Four of these studies provided data on the 
cost of hospitalisation in addition to the cost of relapse over a defined period and are included in 
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both tables 1 and 2 [16,25,27,28]. Thirteen of the studies originated from the US [16,30-41] and a 
further 22 originated from Europe [27,28,42-61]. The majority of studies were bottom up studies 
deriving costs from billing data or from LOS in combination with a reimbursement value per bed day. 
Only two studies [41,68] undertook a top down costing approach in which national estimates of 
expenditure on inpatient care for schizophrenia were divided by a measure of the number of 
inpatient episodes. Most studies excluded children. However, one US study provided data solely on 
children [30]. Most studies limited hospitalisations to episodes associated with a diagnosis of 
schizophrenia, although some studies included all mental health related hospitalisations and two 
studies limited reporting of cost data to all-cause hospitalisations [32,39]. Most studies were 
retrospective analyses of clinical or administrative data. 
Hospitalisation costs in the US ranged from $6,383 to $28,767 (2015 PPP$). The highest costs were 
reported in a study of children and adolescents [30]. Of the remaining US studies the highest cost 
estimate was $22,909 [31]. In Europe, Japan and New Zealand, hospitalisation costs ranged from 
$1,615 to $39,088. The lowest cost derived from Ukrainian data [47] and the second lowest from a 
study set in the Czech Republic [51]. Costs in countries outside the US, Europe, Japan and New 
Zealand ranged from $2,217 to $14,923. Regression analysis of costs indicated no significant change 
over time as reflected by the price year of the study. There was a strong relationship between 
hospitalisation cost and GDP of the relevant country (p<0.001). US based studies were not 
associated with significantly different hospitalisation costs compared with studies from other 
countries. LOS was significant after excluding the dummy for US based studies (p = 0.027) and 
associated with a 0.8% increase in costs for each additional bed day.   
3.3 Relapse costs determined from external sources including expert 
opinion 
The literature on economic evaluations yielded 8 de novo estimates of the cost of relapse derived 
either from publicly available data or expert opinion ranging from $1,895 to $48,847 (2015 PPP$) 
(table 3) [69-76]. Costs of hospital stay were predominantly estimated from national administrative 
data [70,71,74,75] or expert opinion [72,73,76] on LOS, in combination with daily reimbursement 
rates. Assumptions on the total inpatient stay varied from 11d [75] to 111d [70] for admitted 
patients. The latter estimate was derived from UK National Health Service administrative data 
(Hospital Episode Statistics). With the exception of two studies [73,75] inpatient costs were 
supplemented with estimates of additional resource use generated predominantly from expert 
opinion. Two studies assumed further day hospital stay following discharge of 8d [72] and 23d [69]. 
Two studies included accommodation costs following discharge from hospital [69,76], one of which 
generated the largest overall cost estimate [69]. Two publications distinguished costs according to 
whether or not relapse required hospitalisation [72,74], and one study distinguished costs according 
to whether relapse occurred during first or second line treatment [73].The time period over which 
costs were estimated varied from 67 days to 1 year, although the selection of 3 months or 1 year 
was common. Longer periods were not necessarily associated with higher costs. One study 
estimated an annual excess cost of relapse over patients in remission of £20,294 ($33,907, 2015 
PPP$) [70]. 
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4. Discussion 
We found cost estimates for relapse varying from 2,590BRL ($2760; 2015 PPP$) in Brazil [22] to 
417,000SEK ($48,847; 2015 PPP$) in a Swedish setting [69]. Most of the cost estimates are derived 
from literature which either reported a cost of hospitalisation for relapse or reported data from 
which such a cost could be calculated.  These data are highly variable but strongly positively 
associated with GDP per capita. This accords with previous findings of a strong relationship between 
per capita GDP and hospital costs in general [13]. The relationship between mean LOS and 
hospitalisation costs is surprisingly weak. This might indicate differences in treatment intensity 
which compensate for differences in LOS. 
The large variation in costs across different countries is not unexpected. However, there were large 
variations in costs estimates across European countries which might be expected to have similar 
health care unit costs, and indeed the variation in costs across the studies from the US is nearly as 
large as that from European studies. This might be indicative of heterogeneity of populations across 
studies with respect to disease severity and pharmacological treatment. Comparison of costs before 
and after patients initiate depot medication has the potential to select patients with more severe 
disease and to select patients suffering a recent exacerbation of symptoms. In contrast, trials and 
observational cohort studies may select patients with less severe disease, particularly where 
inclusion criteria specify the need for patients to be ‘stable’. 
A smaller portion of the literature reported costs associated with relapse over a specified time 
period. The observed relationship between both overall and excess cost and the length of the 
observation period was unsurprising. However, given the small number of studies, caution should be 
exercised with regard to the magnitude of the increase we found and the assumption that the 
proportionate rise is linear over time. More surprising was the fall in costs for more recent studies. 
The number of studies analysed was small and this finding may be a statistical artefact. However, it 
might indicate a fall in the costs of managing relapse over time attributable to reductions in hospital 
LOS and increased emphasis on managing patients in relapse in the community. There is also a risk 
that the costs of intensive management of relapsing patients in the community are only partially 
captured in administrative databases. The relationship between GDP per capita and costs of relapse 
is weak. This might suggest that after adjusting for differences in purchasing power there is little 
difference in the overall cost of relapse across resource rich and resource poor settings. 
Comparisons between costs of relapse estimated over a defined period and costs of hospitalisation 
for relapse for studies in European settings are confounded by different country settings across the 
two types of study. Focussing on the subgroup of studies from Sweden, Germany and the UK, the 
range of costs is widest for studies reporting a cost of hospitalisation, but it is not evident that 
studies reporting a cost of hospitalisation generate systematically higher or lower costs than studies 
reporting a cost of relapse over a defined period of time. From the US literature, studies estimating a 
cost of hospitalisation generated a similar range of costs to studies estimating an excess cost of 
relapse over a defined period of time, and less than studies estimating an overall cost of relapse. 
Hence we might tentatively conclude that studies reporting a cost of hospitalisation for relapse are 
broadly capturing the excess cost of relapse over patients in remission. Some caution is needed 
here. It is almost certain that hospital costs for patients in relapse substitute for costs of managing 
patients in remission in the community. This may be offset by a tendency for studies reporting costs 
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of hospitalisation to exclude patients with less severe disease and almost certainly less severe 
relapse through the inclusion of only admitted patients. 
4.1 Comparisons with previous studies 
With the exception of a conference presentation we found no previous literature reviewing the cost 
of relapse. The conference abstract reported a range from $1,198 to $50,986 across 11 studies [77]. 
The lower value would appear to be sourced from Daltio et al. [22] and the upper value from Ascher-
Svanum et al. [10] for the subgroup of patients relapsing in both the observation year and the 
previous six months. The authors reported an average cost of €3,421 (2005 Euros) although the 
meaningfulness of a mean cost across such disparate settings is debatable. In their review of the 
costs of compliance Theida and colleagues provide a brief discussion of the (US) literature on the 
cost of relapse, citing four studies and concluding that costs lie in the range of $10,000 to $26,000 
(USD, price year not reported) [78]. 
4.2 Methodological quality of literature 
Methodological concerns arose largely from study design rather than implementation, although it is 
notable that a number of studies failed to state the year of pricing. Large observational cohort 
studies provide the strongest research design to generate evidence on the cost of relapse. Hence it is 
disappointing that many of the large observational cohort studies, with the exception is US-SCAP 
[10] and SOHO [28], have not reported a cost of relapse. Estimates of relapse costs derived from 
administrative data have some limitations: definition of relapse is limited to a measure of resource 
use (typically hospitalisation); there are concerns around the quality of data capture;  the scope of 
data collection is limited to resource use recorded in the database; and true costs may be closer to 
reimbursed values than billed amounts. Nevertheless, both approaches allow estimation of the 
excess cost of relapse. In this respect, they provide a stronger research design than studies 
estimating costs for a cohort of hospitalised patients. The latter study design may also inflate costs 
through selective inclusion of more severely ill patients. Indeed, with the exception of estimates 
based on expert opinion, the highest relapse costs were generated from a cost of hospitalisation 
study [50]. Relapse costs extracted from studies whose primary purpose was to investigate the 
impact of changing drug therapy also merit concern around representativeness of the population 
under study. 
Most studies were limited to a health care perspective by the use of clinical or administrative data. 
Hence there is limited evidence of the impact of relapse on social care costs. Accommodation costs 
may be reduced during periods of hospitalisation but other costs seem likely to rise. We found only 
one report which included indirect costs [24]. That study indicates that additional indirect costs of 
morbidity, mortality and criminal damage related to relapse are modest. Very little data was 
identified on the costs of secure hospitalisation and criminal justice costs associated with relapse. 
Forensic hospitalisations are rarely identified in studies and many cohort studies exclude patient 
hospitalised for long periods of time. UK costs per bed day are 67% higher in secure units compared 
to non-secure psychiatric beds, and such a differential seems likely elsewhere [79]. Studies from the 
US which examined criminal justice costs generally report very modest costs in comparison with 
medical costs (c.f. $1,429 (2001 USD) [80]. Indeed, the increased medication costs of adherent 
patients overwhelm the reductions in criminal justice costs associated with treatment compliance 
[81]. 
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4.3 Strengths and limitations 
The strengths of this review include wide inclusion criteria which sought to capture all of the 
available evidence on the cost of relapse. Where a cost of relapse was not reported but could be 
calculated we have done so. We have tabulated excess costs of relapse over defined time periods, 
where these costs were reported or could be calculated, to facilitate comparison across studies. We 
did not include studies that reported LOS data without attaching costs, although unit cost data is 
readily available, as it was not our aim to provide an exhaustive survey of the literature on the LOS 
following relapse. We searched a limited number of databases and did not undertake double review 
of articles retrieved by the initial search. This may have resulted in the exclusion of relevant studies. 
We did undertake extensive efforts to search articles cited in and citing relevant retrieved studies. 
Finally, we did not undertake a formal assessment of the quality of the studies. Such an assessment 
may not reflect the relative merit of the cost estimates which was frequently not the primary 
objective of the article. Instead we provide readers with contextual data which should guide the 
selection of the most appropriate estimates according to the setting and intended use of the data. 
4 Conclusion 
A number of estimates of the cost of relapse in schizophrenia are discernible from the literature. The 
most robust estimates are derived from prospective cohort studies and analyses of administrative 
databases which indicate excess costs of relapse of $6,033 to $32,753 (2015 PPP$) in the US, and 
$8,665 to $18,676 (2015 PPP$) in Europe. The major portion of reported costs is attributable to 
hospitalisation, but few studies collected cost data outside of health care. Costs of hospitalisation for 
schizophrenia cohorts in relapse showed greater variation, inflenced by large variations in LOS. 
Whilst the scope of data collection in such studies is limited, cost estimates may be inflated by 
inclusion of a more severe case-mix. The cost of relapse is an essential consideration in the 
evaluation of the cost-effectiveness of treating schizophrenia. Sufficient evidence is available to 
challenge the reliance on expert opinion, but additional estimates, especially from large 
observational cohort studies, would be valuable. 
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